J&J's Trem­fya scores 5-year pso­ri­a­sis win in AAD da­ta dump; Roche, Re­gen­eron drugs among lat­est to earn EU ad­vi­so­ry group's nod

In the heat­ed pso­ri­a­sis mar­ket, every play­er is look­ing for a leg up. Now, J&J has long-term ef­fi­ca­cy da­ta show­ing pos­i­tive re­sults for Trem­fya af­ter five years.

A ma­jor­i­ty of mod­er­ate to se­vere pso­ri­a­sis pa­tients treat­ed with the IL-23 in­hibitor post­ed com­plete skin clear­ance af­ter five years of treat­ment, ac­cord­ing to da­ta from the VOY­AGE 2 tri­al pre­sent­ed Fri­day at the vir­tu­al Amer­i­can Acad­e­my Der­ma­tol­ogy an­nu­al meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER